Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-19T04:11:38.372Z Has data issue: false hasContentIssue false
  • English
  • Français

Nerve membrane excitability testing

Published online by Cambridge University Press:  01 February 2008

W. J. Z’Graggen  and
H. Bostock
W. J. Z’Graggen*
Affiliation:
University of Bern, Department of Neurology, Inselspital, Bern, Switzerland
H. Bostock
Affiliation:
Institute of Neurology, Sobell Department of Neurophysiology, London, UK
*
Correspondence to: Werner J. Z’Graggen, Department of Neurology, Inselspital, University of Bern, CH-3010 Bern, Switzerland. E-mail: werner.zgraggen@insel.ch; Tel: +41 31 632 21 11; Fax: +41 31 632 30 11
Get access

Summary

Routine motor nerve conduction studies measure latencies, conduction velocities and amplitudes of compound action potentials. These measurements can be very useful in defining the pathology, while they provide little insight into the underlying disease mechanisms. Increasingly, the technique of ‘threshold tracking’ is being used in research and clinical studies on large myelinated axons. Nerve excitability testing is a non-invasive approach in investigating the pathophysiology of peripheral nerve disorders, which determines the electrical properties of the nerve membrane at the site of stimulation. We have found evidence that in patients with critical illness polyneuropathy peripheral nerves are depolarized. The correlations with serum factors suggest that this membrane depolarization is related to endoneurial hyperkalemia and/or hypoxia. While other mechanisms of depolarization may well be involved, the degree to which potential-sensitive nerve excitability indices are related to serum potassium and bicarbonate suggests that other factors, independent of potassium and acid–base balance, are likely to be of relatively minor significance.

Keywords

DEPOLARIZATIONAXONSNERVE CONDUCTIONMEASUREMENT AND MONITORINGPROGNOSIS
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 25 , Issue S42 , February 2008 , pp. 68 - 72
Copyright
Copyright © European Society of Anaesthesiology 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bergmans, J. The Physiology of Single Human Nerve Fibres. Belgium: Vander: University of Louvain, 1970.Google ScholarPubMed
2.Raymond, SA. Effects of nerve impulses on threshold of frog sciatic nerve fibres. J Physiol 1979; 290: 273–303.CrossRefGoogle ScholarPubMed
3.Burke, D, Kiernan, MC, Bostock, H. Excitability of human axons. Clin Neurophysiol 2001; 112: 1575–1585.CrossRefGoogle ScholarPubMed
4.Bostock, H, Cikurel, K, Burke, D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21: 137–158.3.0.CO;2-C>CrossRefGoogle Scholar
5.Kiernan, MC, Bostock, H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000; 123 (Pt 12): 2542–2551.CrossRefGoogle ScholarPubMed
6.Kiernan, MC, Cikurel, K, Bostock, H. Effects of temperature on the excitability properties of human motor axons. Brain 2001; 124: 816–825.CrossRefGoogle ScholarPubMed
7.Blight, AR. Computer simulation of action potentials and afterpotentials in mammalian myelinated axons: the case for a lower resistance myelin sheath. Neuroscience 1985; 15: 13–31.CrossRefGoogle ScholarPubMed
8.Bowe, CM, Kocsis, JD, Waxman, SG. The association of the supernormal period and the depolarizing afterpotential in myelinated frog and rat sciatic nerve. Neuroscience 1987; 21: 585–593.CrossRefGoogle ScholarPubMed
9.David, G, Modney, B, Scappaticci, KA, Barrett, JN, Barrett, EF. Electrical and morphological factors influencing the depolarizing after-potential in rat and lizard myelinated axons. J Physiol 1995; 489 (Pt 1): 141–157.CrossRefGoogle ScholarPubMed
10.Bostock, H, Rothwell, JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol 1997; 498 (Pt 1): 277–294.CrossRefGoogle ScholarPubMed
11.Bostock, H, Baker, M. Evidence for two types of potassium channel in human motor axons in vivo. Brain Res 1988; 462: 354–358.CrossRefGoogle ScholarPubMed
12.Kiernan, MC, Burke, D, Andersen, KV, Bostock, H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000; 23: 399–409.3.0.CO;2-G>CrossRefGoogle ScholarPubMed
13.Kiernan, MC, Lin, CS, Andersen, KV, Murray, NM, Bostock, H. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001; 24: 883–892.CrossRefGoogle ScholarPubMed
14.Kiernan, MC, Guglielmi, JM, Kaji, R, Murray, NM, Bostock, H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002; 125: 664–675.CrossRefGoogle ScholarPubMed
15.Kiernan, MC, Walters, RJ, Andersen, KV, Taube, D, Murray, NM, Bostock, H. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002; 125: 1366–1378.CrossRefGoogle ScholarPubMed
16.Bostock, H, Campero, M, Serra, J, Ochoa, J. Velocity recovery cycles of C fibres innervating human skin. J Physiol 2003; 553: 649–663.CrossRefGoogle ScholarPubMed
17.Schilling, T, Heinrich, B, Kau, R et al. . Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology 1997; 54: 89–95.CrossRefGoogle ScholarPubMed
18.Kanai, K, Kuwabara, S, Arai, K, Sung, JY, Ogawara, K, Hattori, T. Muscle cramp in Machado–Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003; 126: 965–973.CrossRefGoogle ScholarPubMed
19.Bostock, H, Sharief, MK, Reid, G, Murray, NM. Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 1995; 118 (Pt 1): 217–225.CrossRefGoogle ScholarPubMed
20.Horn, S, Quasthoff, S, Grafe, P, Bostock, H, Renner, R, Schrank, B. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve 1996; 19: 1268–1275.CrossRefGoogle ScholarPubMed
21.Kiernan, MC, Hart, IK, Bostock, H. Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 2001; 70: 56–64.CrossRefGoogle ScholarPubMed
22.Nodera, H, Bostock, H, Kuwabara, S et al. . Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 2004; 127: 203–211.CrossRefGoogle ScholarPubMed
23.Kiernan, MC, Isbister, GK, Lin, CS, Burke, D, Bostock, H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 2005; 57: 339–348.CrossRefGoogle ScholarPubMed
24.Z’Graggen, WJ, Lin, CS, Howard, RS, Beale, RJ, Bostock, H. Nerve excitability changes in critical illness polyneuropathy. Brain 2006; 129: 2461–2470.CrossRefGoogle ScholarPubMed
25.Bostock, H, Walters, RJ, Andersen, KV, Murray, NM, Taube, D, Kiernan, MC. Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant 2004; 19: 1054–1057.CrossRefGoogle Scholar
26.Latronico, N, Peli, E, Botteri, M. Critical illness myopathy and neuropathy. Curr Opin Crit Care 2005; 11: 126–132.CrossRefGoogle ScholarPubMed